The FDA has been busy this month. Review some of the biggest FDA-related stories of October, including big news from scPharmaceuticals, Abiomed, Bristol Myers Squibb and MedAlliance, in our monthly roundup. 

The new guidance document was designed to help cardiologists and other clinicians deliver the best care possible when treating ASCVD patients who present with additional conditions that need to be considered. 

Patients impacted by this recall are advised to speak with a physician about how to proceed. 

“The findings of this study are important because they provide fresh evidence that the use of e-cigarettes could interfere with normal heart rhythms—something we did not know before,” according to one specialist. 

The acquisition includes an initial investment of $35 million and an upfront closing payment of $200 million. By 2029, if the companies reach all targeted regulatory and commercial milestones, the acquisition could cost Cordis up to $1.135 billion in all.

The new meta-analysis, published in Frontiers in Cardiovascular Medicine, included data from 58 million patients. “We hope our findings will help mitigate vaccine hesitancy and increase vaccine uptake," one researcher said. 

The connection between cognitive impairment and postoperative delirium among TAVR patients stood out as a definite concern to the study's authors.

CMS stated the code would have an assigned payment rate of $900-$1,000. It became effective starting on October 1, 2022. 

Ricardo Cury, MD, chairman of radiology and director of cardiac imaging, Baptist Health South Florida and Miami Cardiac and Vascular Institute, discusses the new CAD-RADS 2.0 cardiac imaging reporting criteria.